# EDGAR Filing Document

**Accession Number:** 0001809122
**File Stem:** 0001213900-25-121266
**Filing Date:** 2025-12
**Character Count:** 9057
**Document Hash:** ab0da07f4770d2f8cc377375b95eef94
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-121266.hdr.sgml**: 20251212

**ACCESSION NUMBER**: 0001213900-25-121266

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251212

**DATE AS OF CHANGE**: 20251212

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CureVac N.V.
- **CENTRAL INDEX KEY:** 0001809122
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-91630
- **FILM NUMBER:** 251569061

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FRIEDRICH-MIESCHER-STRASSE 15
- **CITY:** TUBINGEN
- **NON US STATE TERRITORY:** BADEN-WURTTEMBERG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 72076
- **BUSINESS PHONE:** 49 7071 9883 0

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** FRIEDRICH-MIESCHER-STRASSE 15
- **CITY:** TUBINGEN
- **NON US STATE TERRITORY:** BADEN-WURTTEMBERG
- **PROVINCE COUNTRY:** 2M
- **ZIP:** 72076

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CureVac B.V.
- **DATE OF NAME CHANGE:** 20200410
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Hothum Mathias
- **CENTRAL INDEX KEY:** 0001918385

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**MAIL ADDRESS:**
- **STREET 1:** BUERGERMEISTER-WILLINGER-STRASSE 3
- **CITY:** WALLDORF
- **STATE:** 2M
- **ZIP:** 69190

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 3)**

**CureVac N.V.**

*(Name of Issuer)*

**Common Shares, par value (euro)0.12 per share**

*(Title of Class of Securities)*

**N2451R105**

*(CUSIP Number)*

**Brian S. North, Esquire**<br>Buchanan Ingersoll & Rooney PC<br>50 South 16th Street, Suite 3200<br>Philadelphia PA 19102<br>(215) 665-8700

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/10/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **N2451R105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**MH-LT-Investments GmbH** | Name of reporting person<br>**MH-LT-Investments GmbH** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.00%** | Percent of class represented by amount in Row (11)<br>**0.00%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**OO** | Type of Reporting Person (See Instructions)<br>**OO** | |

---

| **CUSIP No.** | **N2451R105** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Dr. Matthias Hothum** | Name of reporting person<br>**Dr. Matthias Hothum** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**2M** | Citizenship or place of organization<br>**2M** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**0.00** | Aggregate amount beneficially owned by each reporting person<br>**0.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**0.00%** | Percent of class represented by amount in Row (11)<br>**0.00%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Shares, par value (euro)0.12 per share

**(b) Name of Issuer:**
CureVac N.V.

**(c) Address of Issuer's Principal Executive Offices:**
Friedrich-Miescher-Strasse 15, Tubingen, 2M, 72076

This Amendment is being filed to reflect the completion of the Reporting Persons' exchange all of the Shares beneficially owned by them pursuant to an exchange offer (the "Exchange Offer") made by BioNTech SE, a European stock corporation ("BioNTech").

This Amendment is the final amendment to the Schedule 13D by the Reporting Persons and constitutes an "exit filing" by them.

**Item 4. Purpose of Transaction**

The Reporting Persons have tendered all of their Shares into the Exchange Offer. The Exchange Offer expired as scheduled at 9:00 a.m. Eastern Time on December 3, 2025. The Shares tendered by the Reporting Persons were accepted for exchange and transferred to BioNTech in a capital increase for the issue of shares in BioNTech underlying the American Depository Shares of BioNTech offered as consideration of the Exchange Offer which took effect upon registration on December 10, 2025. As a result, the Reporting Persons no longer beneficially own, or otherwise hold, any securities of the Issuer.

The Reporting Persons expect to receive full consideration to which they are entitled under the Exchange Offer (the "Completion") on or about December 15, 2025.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The information required by Items 5(a) and (b) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person. The Reporting Persons tendered all of their Shares in the Exchange Offer and, as a result of the issuance by BioNTech of its securities in the Exchange Offer on December 10, 2025, the Reporting Persons no longer beneficially own any Shares.

**(b)**
The information required by Items 5(a) and (b) is set forth in Rows 7 - 13 of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.

**(c)**
Other than the transaction described in Item 5(a) no Reporting Person has effected any transaction in the Shares during the past sixty (60) days

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** MH-LT-Investments GmbH

**Signature:** /s/ Dr. Christina Eschenfelder

**Name/Title:** Dr. Christina Eschenfelder/Attorney-in-fact

**Date:** 12/12/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Dr. Matthias Hothum

**Signature:** /s/ Dr. Christina Eschenfelder as attorney-in-fact

**Name/Title:** MATTHIAS HOTHUM

**Date:** 12/12/2025